Trade Amgen - AMGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.21 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 269.35 |
| Open | 268.95 |
| 1-Year Change | 9.99% |
| Day's Range | 268.95 - 271.04 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 26, 2024 | 269.92 | 3.81 | 1.43% | 266.11 | 271.54 | 264.68 |
| Apr 25, 2024 | 269.35 | -3.88 | -1.42% | 273.23 | 274.05 | 267.08 |
| Apr 24, 2024 | 272.99 | 2.84 | 1.05% | 270.15 | 274.76 | 268.98 |
| Apr 23, 2024 | 273.45 | 1.57 | 0.58% | 271.88 | 274.41 | 270.59 |
| Apr 22, 2024 | 271.88 | 2.04 | 0.76% | 269.84 | 272.97 | 269.46 |
| Apr 19, 2024 | 268.81 | 5.87 | 2.23% | 262.94 | 269.27 | 259.97 |
| Apr 18, 2024 | 262.60 | -1.42 | -0.54% | 264.02 | 265.76 | 262.37 |
| Apr 17, 2024 | 263.94 | -3.01 | -1.13% | 266.95 | 268.49 | 263.17 |
| Apr 16, 2024 | 265.48 | -0.60 | -0.23% | 266.08 | 266.34 | 263.83 |
| Apr 15, 2024 | 265.25 | -2.85 | -1.06% | 268.10 | 270.27 | 264.09 |
| Apr 12, 2024 | 267.12 | -1.33 | -0.50% | 268.45 | 268.78 | 266.03 |
| Apr 11, 2024 | 269.88 | 0.73 | 0.27% | 269.15 | 272.72 | 268.21 |
| Apr 10, 2024 | 266.20 | -1.57 | -0.59% | 267.77 | 267.77 | 264.19 |
| Apr 9, 2024 | 270.27 | 0.72 | 0.27% | 269.55 | 271.16 | 268.38 |
| Apr 8, 2024 | 269.01 | 1.36 | 0.51% | 267.65 | 270.03 | 267.14 |
| Apr 5, 2024 | 269.87 | 4.86 | 1.83% | 265.01 | 272.96 | 263.98 |
| Apr 4, 2024 | 267.89 | -7.82 | -2.84% | 275.71 | 276.48 | 267.70 |
| Apr 3, 2024 | 274.31 | -0.75 | -0.27% | 275.06 | 276.29 | 273.53 |
| Apr 2, 2024 | 276.01 | -6.18 | -2.19% | 282.19 | 283.34 | 275.96 |
| Apr 1, 2024 | 282.97 | 1.17 | 0.42% | 281.80 | 283.43 | 278.80 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Amgen Company profile
About Amgen, Inc.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).
Equity composition
Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).
| Industry: | Pharmaceuticals (NEC) |
One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com